Sheila Gujrathi, M.D.

Board Chair

Dr. Sheila Gujrathi is the co-founder of Gossamer Bio, a new biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs of targeted patient populations in immunology, inflammation, fibrosis and oncology. Prior to that, she most recently served as chief medical officer of Receptos, an immunology-focused biotechnology company that was acquired by Celgene in August 2015 for $7.2 billion. At Receptos, she built the clinical development organization and advanced the pipeline of drug candidates, including Phase 3 programs in multiple sclerosis and ulcerative colitis. Previously, Dr. Gujrathi was vice president of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb (BMS). There she led late-stage clinical development and supported regulatory filings for Orencia® and Nulojix®. She was also responsible for development of other assets in the BMS immunology clinical pipeline, and advised the strategies for discovery, early development and external business development within the immunoscience franchise. Prior to BMS, Dr. Gujrathi held roles in the immunology, tissue growth and repair clinical development groups at Genentech and served as the Avastin franchise team leader. Earlier in her career, she was also a management consultant in McKinsey & Company’s healthcare practice.

Dr. Gujrathi received her M.D. in the accelerated Honors Program in Medical Education and her B.S. in biomedical engineering with highest distinction from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women’s Hospital, Harvard Medical School and additional fellowship training in allergy/immunology at UCSF and Stanford. She currently serves on the board of directors at Five Prime Therapeutics and previously served as a director for Ambrx, which was acquired in June 2015.

ltBlueRP03 ltBlueRP02left ltBlueRP02left